Fibroblast Activation Protein Inhibitor (FAPI) PET Imaging in Sarcomas: A New Frontier in Nuclear Medicine

被引:4
|
作者
Giammarile, Francesco [1 ]
Knoll, Peter [1 ]
Paez, Diana [1 ]
Lobato, Enrique Estrada [1 ]
Teran, Adriana K. Calapaqui [2 ,3 ]
Bolton, Roberto C. Delgado [4 ,5 ,6 ]
机构
[1] IAEA, Dept Nucl Sci & Applicat, Nucl Med & Diagnost Imaging Sect, Vienna, Austria
[2] Univ Hosp Marques de Valdecilla, Dept Pathol, Santander, Spain
[3] Inst Invest Sanitaria Valdecilla IDIVAL, Santander, Spain
[4] Univ Hosp San Pedro, Dept Diagnost Imaging Radiol & Nucl Med, Logrono, La Rioja, Spain
[5] Ctr Biomed Res La Rioja CIBIR, Logrono, La Rioja, Spain
[6] Serv Cantabro Salud, Santander, Spain
关键词
D O I
10.1053/j.semnuclmed.2024.01.001
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The field of nuclear medicine has witnessed significant advancements in recent years, particularly in the area of PET imaging. One such development is the use of Fibroblast Activation Protein Inhibitors (FAPI) as a novel radiotracer. FAPI PET imaging has shown promising results in various malignancies, including sarcomas, which are a diverse group of cancers originating from mesenchymal cells. This paper aims to explore the potential of FAPI PET imaging in the diagnosis, staging, and treatment monitoring of sarcomas. Several studies have demonstrated the potential of FAPI PET in sarcomas. Furthermore, FAPI PET imaging has shown potential in assessing treatment response, with changes in FAPI uptake correlating with treatment outcomes. However, there are challenges to be addressed. The heterogeneity of sarcomas, both inter- and intra-tumoral, may affect the uniformity of Fibroblast Activation Protein (FAP) expression and thus the effectiveness of FAPI PET imaging. Additionally, the optimal timing and dosage of FAPI for PET imaging in sarcomas need further investigation. In conclusion, the introduction of FAPI PET imaging represents a significant advancement in the field of nuclear medicine and oncology. The ability to target FAP, a protein overexpressed in the majority of sarcomas, offers new possibilities for the diagnosis and treatment of these complex and diverse tumors. Its potential applications in diagnosis, staging, and theranostics are vast, and on -going research continues to explore and address its limitations. As we continue to deepen our understanding of this novel imaging technique, it is hoped that FAPI PET imaging will play an increasingly important role in the fight against cancer. However, as with any new technology, further research is needed to fully understand the potential and limitations of FAPI PET imaging in the clinical setting. Semin Nucl Med 54:340-344 (c) 2024 Elsevier Inc. All rights reserved.
引用
收藏
页码:340 / 344
页数:5
相关论文
共 50 条
  • [21] Substrate Study for Dihydroxyboryl Astatine Substitution Reaction with Fibroblast Activation Protein Inhibitor (FAPI)
    Aso, Ayaka
    Kaneda-Nakashima, Kazuko
    Nabetani, Hinako
    Kadonaga, Yuichiro
    Shirakami, Yoshifumi
    Watabe, Tadashi
    Yoshiya, Taku
    Mochizuki, Masayoshi
    Koshino, Yuki
    Ooe, Kazuhiro
    Kawakami, Atsuko
    Jinno, Naoya
    Toyoshima, Atsushi
    Haba, Hiromitsu
    Wang, Yang
    Cardinale, Jens
    Giesel, Frederik L.
    Shimoyama, Atsushi
    Fukase, Koichi
    CHEMISTRY LETTERS, 2022, 51 (11) : 1091 - 1094
  • [22] Fibroblast Activation Protein Inhibitor PET/CT in Gastric Cancer
    Watabe, Tadashi
    Giesel, Frederik L.
    PET CLINICS, 2023, 18 (03) : 337 - 344
  • [23] 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial
    Kessler, Lukas
    Hirmas, Nader
    Pabst, Kim M.
    Hamacher, Rainer
    Ferdinandus, Justin
    Schaarschmidt, Benedikt M.
    Milosevic, Aleksandar
    Nader, Michael
    Umutlu, Lale
    Uhl, Waldemar
    Reinacher-Schick, Anke
    Lugnier, Celine
    Witte, David
    Niedergethmann, Marco
    Herrmann, Ken
    Fendler, Wolfgang P.
    Siveke, Jens T.
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64 (12) : 1910 - 1917
  • [24] Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04
    Varasteh, Zohreh
    Mohanta, Sarajo
    Robu, Stephanie
    Braeuer, Miriam
    Li, Yuanfang
    Omidvari, Negar
    Topping, Geoffrey
    Sun, Ting
    Nekolla, Stephan G.
    Richter, Antonia
    Weber, Christian
    Habenicht, Andreas
    Haberkorn, Uwe A.
    Weber, Wolfgang A.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (12) : 1743 - 1749
  • [25] The Role of Fibroblast Activation Protein Ligands in Oncologic PET Imaging
    Dendl, Katharina
    Schlittenhardt, Joel
    Staudinger, Fabian
    Kratochwil, Clemens
    Altmann, Anette
    Haberkorn, Uwe
    Giesel, Frederik L.
    PET CLINICS, 2021, 16 (03) : 341 - 351
  • [26] PET imaging to assess fibroblast activation protein inhibitor biodistribution: A training program adapted to pharmacology education
    Ge, Luna
    Song, Guanhua
    Zhang, Yuang
    Pan, Jihong
    Zhang, Yihang
    Wang, Lin
    Cheng, Kai
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2022, 10 (04):
  • [27] Highlighting Fibroblasts Activation in Fibrosis: The State-of-The-Art Fibroblast Activation Protein Inhibitor PET Imaging in Cardiovascular Diseases
    Cui, Yan
    Wang, Yuxiang
    Wang, Shu
    Du, Bulin
    Li, Xuena
    Li, Yaming
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (18)
  • [28] Fibroblast Activation Protein (FAPI) Specific PET for Advanced Target Volume Delineation in Head and Neck Cancer
    Syed, M.
    Flechsig, P.
    Liermann, J.
    Windisch, P.
    Haberkorn, U.
    Debus, J.
    Adeberg, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E383 - E383
  • [29] Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours
    Kreppel, Barbara
    Gonzalez-Carmona, Maria Angeles
    Feldmann, Georg
    Kuppers, Jim
    Moon, Euy Sung
    Marinova, Milka
    Bundschuh, Ralph Alexander
    Kristiansen, Glen
    Essler, Markus
    Roesch, Frank
    Gaertner, Florian Christoph
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2021, 60 (05): : 344 - 354
  • [30] PET/CT: a new imaging technology in nuclear medicine
    Heiko Schöder
    Yusuf E. Erdi
    Steven M. Larson
    Henry W. D. Yeung
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 1419 - 1437